Navigation Links
Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
Date:10/18/2010

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo®... -- POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study

   

Call Scheduled for Tuesday, October 19, 2010 at 8:00 a.m. EDT

POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it will host a conference call to discuss the recently announced preliminary analysis of the Intermezzo® highway driving study.Conference Call Information Date: Tuesday, October 19, 2010Time: 8:00 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until November 23, 2010.

A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business October 23, 2010. The replay telephone numbers are 800-642-1687 (U.S.) and 706-645-9291 (International), replay passcode: 19398284.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
2. Transcept Pharmaceuticals to Present at BIO Investor Forum
3. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
4. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
5. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
6. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
9. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
10. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
11. Transcept Pharmaceuticals to Report First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Today, Analytics 4 Life (A4L), ... announced its expansion into JLABS @ Toronto ... science incubators. As a resident in the space, A4L ... device development and commercialization expertise. JLABS @ ... innovation center that provides a flexible environment for start-up ...
(Date:1/15/2017)... , January 16, 2017 Le conseil ... à base de collagène pour la régénération de tissus humains, ... poste de directeur général avec effet immédiat. ... Bill est un dirigeant ... occupé plusieurs postes de gestion générale et de direction au ...
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad ... offering complimentary consultations and financing for orthodontics for a limited time. Complimentary for ... learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. Ben ... in 3-D scanning device which is capable of taking digital impressions of teeth and ... such as CAD CAM restorations , in terms of speed, efficiency and patient ...
(Date:1/15/2017)... ... ... is announcing the release of an updated version of their top selling clipper, the ... wide jaws that will accommodate nails up to 4mm in thickness . Nails like ... reinforced for extra strength when pressing down on dense nails which can be a hindrance ...
(Date:1/15/2017)... , ... January 15, 2017 , ... The Gravity Vault ... in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, ... Vaults sixth location, including three in New Jersey and two in New York. With ...
Breaking Medicine News(10 mins):